Flinders University Professor of Medicine Nikolai Petrovsky, who founded Vaxine Pty Ltd, a company funded by the US National Institutes of Health to develop novel vaccine technologies.
CREDIT
Flinders University
A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Learn more: Possible dementia vaccine closer after mice studies
Go deeper with Bing News on:
Dementia vaccine
- Freedom Plasma Opens Up A Location In St. Petersburg
READ MORE: The US Is In Process Of Releasing Monkeypox Vaccine From National Stockpile ... limiting the effects of Alzheimer’s Disease and dementia,” said Jerome Parnell III, CEO of ImmunoTek.
- Cancer And Dementia Patients Face Higher Risk Of Breakthrough Covid, Studies Find
Vaccinated people with cancer or dementia face a higher risk of contracting breakthrough Covid-19 infections, according to a pair of new studies, leading researchers to argue high-risk patients still ...
- Viral Vaccines Market Size, And Analysis, Trends, Recent Developments, And Forecast Till 2030
Key Companies Covered in the Viral Vaccines Market Research Report Are Serum Institute of India Pvt. Ltd., Pfizer, Johnson & Johnson, Ast ...
- Time Capsule buried in UCL's world-class centre for neuroscience as part of Dementia Action Week
An Iceland plastic carrier bag, a Covid-19 vaccine vial and a piece of stainless steel have been buried in a time capsule of a new world-class centre for neuroscience at UCL.
- What to Know About the Alzheimer’s Vaccines Currently in Development
Below are the Alzheimer’s disease vaccines currently undergoing clinical trials. Many, but not all, people with Alzheimer’s disease will have a buildup of beta-amyloid plaques. It’s not clear exactly ...
Go deeper with Google Headlines on:
Dementia vaccine
Go deeper with Bing News on:
Vaccine
- China’s insistence on a homegrown mRNA vaccine haunts its COVID-control efforts
China is trying to tackle its biggest coronavirus outbreak without a tool it could have adopted months ago: Western-developed mRNA COVID-19 vaccines.
- Covid-19 Vaccine and Drug Sales, Once Booming, Plateau
Merck, J&J and some other drugmakers are dialing back sales estimates now that supplies are ample and many people are vaccinated.
- Germany's vaccine panel says one COVID shot enough for children
Germany's vaccine advisory panel on Tuesday said one COVID-19 shot was enough for healthy five to 11 year-olds because most of them had already undergone an infection, be it known of undetected.
- Smallpox Vaccine Enters Wider Production Amid Monkeypox Outbreak
Bavarian Nordic has fielded requests from dozens of countries seeking the shot, CEO Paul Chaplin says.
- As Monkeypox Cases Rise, Nations Are Urged to Examine Vaccine Stores
The United States has stockpiled millions of doses of two smallpox vaccines, also effective against monkeypox. But the outbreaks so far are clustered in other countries.
